PMV PHARMACEUTICALS, INC. Proceeds from Sale and Maturity of Marketable Securities
PMV PHARMACEUTICALS, INC. (PMVP) reported Proceeds from Sale and Maturity of Marketable Securities of $46.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $14.50M, a 65.42% decline year-over-year.
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $31.50M, a 29.13% decline year-over-year.
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $39.50M, a 12.40% decline year-over-year.
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $32.50M, a 42.47% decline year-over-year.
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $158.37M, a 21.61% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $202.04M, a 18.18% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $170.96M, a 27.50% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $235.81M, a 105.75% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $46.00M 10-Q · filed 2026-08-14 | $85.50M derived: sum of 3 quarters · filed 2026-08-14 | $118.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $31.50M 10-Q · filed 2026-05-12 | $71.00M derived: sum of 2 quarters · filed 2026-05-12 | $103.50M derived: sum of 3 quarters · filed 2026-05-12 | $145.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $39.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $72.00M derived: sum of 2 quarters · filed 2026-03-06 | $113.93M derived: sum of 3 quarters · filed 2026-08-14 | $158.37M 10-K · filed 2026-03-06 |
| 2025-09-30 | $32.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $74.43M derived: sum of 2 quarters · filed 2026-08-14 | $118.87M 10-Q · filed 2025-11-12 | $163.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $41.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $86.37M 10-Q · filed 2026-08-14 | $131.47M derived: sum of 3 quarters · filed 2026-08-14 | $187.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $44.45M 10-Q · filed 2026-05-12 | $89.54M derived: sum of 2 quarters · filed 2026-05-12 | $146.03M derived: sum of 3 quarters · filed 2026-05-12 | $189.24M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $45.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $101.58M derived: sum of 2 quarters · filed 2026-03-06 | $144.79M derived: sum of 3 quarters · filed 2026-03-06 | $202.04M 10-K · filed 2026-03-06 |
| 2024-09-30 | $56.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $99.70M derived: sum of 2 quarters · filed 2025-11-12 | $156.95M 10-Q · filed 2025-11-12 | $187.95M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $43.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $100.46M 10-Q · filed 2025-08-07 | $131.46M derived: sum of 3 quarters · filed 2026-03-06 | $155.46M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $57.25M 10-Q · filed 2025-05-09 | $88.25M derived: sum of 2 quarters · filed 2026-03-06 | $112.25M derived: sum of 3 quarters · filed 2026-03-06 | $154.90M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $55.00M derived: sum of 2 quarters · filed 2026-03-06 | $97.65M derived: sum of 3 quarters · filed 2026-03-06 | $170.96M 10-K · filed 2026-03-06 |
| 2023-09-30 | $24.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $66.65M derived: sum of 2 quarters · filed 2024-11-07 | $139.96M 10-Q · filed 2024-11-07 | $199.50M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $42.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $115.95M 10-Q · filed 2024-08-08 | $175.50M derived: sum of 3 quarters · filed 2025-03-03 | $252.35M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $73.30M 10-Q · filed 2024-05-09 | $132.85M derived: sum of 2 quarters · filed 2025-03-03 | $209.70M derived: sum of 3 quarters · filed 2025-03-03 | $253.44M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $59.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $136.40M derived: sum of 2 quarters · filed 2025-03-03 | $180.14M derived: sum of 3 quarters · filed 2025-03-03 | $235.81M 10-K · filed 2025-03-03 |
| 2022-09-30 | $76.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $120.59M derived: sum of 2 quarters · filed 2023-11-09 | $176.27M 10-Q · filed 2023-11-09 | $205.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $43.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $99.42M 10-Q · filed 2023-08-09 | $128.91M derived: sum of 3 quarters · filed 2024-02-29 | $178.66M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $55.68M 10-Q · filed 2023-05-10 | $85.17M derived: sum of 2 quarters · filed 2024-02-29 | $134.93M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $29.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $79.25M derived: sum of 2 quarters · filed 2024-02-29 | $114.61M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $49.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $85.11M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $35.36M 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $7.97M derived: sum of 2 quarters · filed 2023-03-01 | $34.08M derived: sum of 3 quarters · filed 2023-03-01 | $42.57M 10-K · filed 2023-03-01 |
| 2020-09-30 | $7.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $34.08M derived: sum of 2 quarters · filed 2021-11-12 | $42.57M 10-Q · filed 2021-11-12 | $49.14M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $26.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $34.60M 10-Q · filed 2021-08-13 | $41.17M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2020-03-31 | $8.49M 10-Q · filed 2021-05-14 | $15.06M derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $6.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $46.79M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $40.22M 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $70.82M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |